Skip to main content

Table 1 Baseline demographic, anthropometric, clinical and routine laboratory characteristics of the study participants

From: Soluble Klotho is associated with mortality and cardiovascular events in hemodialysis

Baseline Characteristics Total Population, n = 79 Klotho≤745, n = 40 Klotho> 745, n = 39 P
Male, n(%) 50 (63.3) 26 (65.5%) 24 (61.5%) 0.750
Age (years) 59.7 ± 15.8 61.5 ± 16.1 58.1 ± 15.0 0.158
ΒΜΙ (kg/m2) 24.7 ± 4.1 25.3 ± 4.6 24.3 ± 3.6 0.307
Dialysis vintage (months) 65.5 ± 54.3 63.7 ± 52.5 70.5 ± 57.3 0.583
Hypertension, n (%) 57 (72.2%) 33 (82.5%) 24 (61.5%) 0.038
Diabetes, n (%) 17 (21.5%) 11 (27.5%) 6 (15.4%) 0.190
CVD history, n (%) 29 (36.7%) 18 (45.0%) 11 (28.2%) 0.122
Smokers, n(%) 25 (31.6%) 11 (27.5%) 14 (35.9%) 0.422
SBP (mmHg) 136.7 ± 18.4 136.2 ± 18.4 138.4 ± 17.6 0.621
DBP (mmHg) 84.1 ± 11.6 84.9 ± 12.8 84.1 ± 10.5 0.619
Pulse pressure (mmHg) 53.0 ± 13.9 49.7 ± 12.7 54.2 ± 16.2 0.322
cfPWV (m/s) 9.9 ± 2.3 10.1 ± 2.5 9.8 ± 2.1 0.565
ccIMT (mm) 0.83 ± 0.16 0.86 ± 0.16 0.79 ± 0.15 0.034
Klotho (pg/mL) 796.1 ± 236.8 661.3 ± 74.5 934.4 ± 265.7 < 0.001
iFGF23(pg/mL) 794.4 ± 1393.7 879.7 ± 1449.7 726.2 ± 1401.8 0.151
cFGF23(RU/mL) 6730.8 ± 10,113.0 6777.1 ± 11,211.3 6733.0 ± 9367.1 0.638
kt/v 1.46 ± 0.21 1,48 ± 0.20 1.44 ± 0.22 0.409
HDF 34 (43%) 15 (37.5%) 19 (48.7%) 0.314
Hemoglobin (g/dl) 11.3 ± 1.1 11.4 ± 1.3 11.3 ± 1.1 0.814
Creatinine (mg/dl) 9.24 ± 2.11 9.14 ± 1.89 9.34 ± 2.32 0.715
Urea (mg/dl) 132.7 ± 33.2 122.8 ± 29.9 138.3 ± 33.6 0.199
Albumin (g/dl) 4.02 ± 0.33 4.03 ± 0.34 3.97 ± 0.38 0.426
Cholesterol (mg/dl) 150.8 ± 38.8 151.7 ± 49.1 152.5 ± 29.3 0.433
Triglycerides (mg/dl) 140.2 ± 64.4 150.5 ± 68.6 128.9 ± 39.3 0.201
LDL-Cholesterol (mg/dl) 74.1 ± 32.1 78.5 ± 42.1 72.9 ± 23.3 0.442
HDL-Cholesterol (mg/dl) 45.1 ± 14.1 43.6 ± 13.9 48.4 ± 14.7 0.078
Serum calcium (mg/dl) 8.84 ± 0.70 8.83 ± 0.77 8.78 ± 0.60 0.316
Serum phosphate (mg/dl) 5.23 ± 1.45 5.08 ± 1.42 5.36 ± 1.56 0.834
Ca x P (mg2/dl2) 46.3 ± 13.3 46.9 ± 13.8 46.3 ± 13.1 0.869
iPTH (pmol/L) 38.5 ± 29.4 38.9 ± 31.9 39.2 ± 28.0 0.673
Alkaline phosphatase (U/L) 94.4 ± 40.2 95.9 ± 44.9 101.4 ± 40.5 0.267
CRP (mg/L) 7.34 ± 9.39 9.51 ± 13.56 5.94 ± 5.96 0.342
Intake of antihypertensive agents 57 (72.2%) 33 (82.5%) 24 (61.5%) 0.038
ESA 61 (77.2%) 30 (75%) 31 (79.5%) 0.479
Vit D and analogues 45 (57%) 22 (55%) 23 (59%) 0.721
Intravenous Iron 71 (89.9%) 35 (87.5%) 36 (92.3%) 0.479
Statins 29 (36.7%) 17 (42.5%) 12 (30.8%) 0.279
  1. Abbreviations: BMI Body mass index, Ca x P Calcium x phosphorus product, ccIMT Common carotid Intima Media Thickness, cFGF-23 c-terminal Fibroblast Growth Factor 23, cfPWV Carotid - femoral Pulse Wave Velocity, CRP c-reactive protein, CVD Cardiovascular disease, DBP Diastolic blood pressure, ESA Erythropoiesis stimulating agent, HDL High density lipoprotein, HDF Hemodiafiltration, iFGF-23 Intact Fibroblast Growth Factor 23, LDL Low density lipoprotein, iPTH Intact parathormone, SBP Systolic blood pressure. Hypertension is defined as predialysis SBP ≥ 140 mmHg or DBP ≥ 90 mmHg, or use of antihypertensive drugs. Smoker status is defined as regular tobacco use or smoking cessation within the previous year. Cardiovascular disease history includes the coronary artery disease, ischemic or hemorrhagic stroke or peripheral occlusive arterial disease defined as the presence of aortic aneurysm or intermittent claudication or previous peripheral angioplasty